Existence of a commitment program for mitosis in early G1 in tumour cells.
The proliferation of normal non-tumourigenic mouse fibroblasts is stringently controlled by regulatory mechanisms located in the postmitotic stage of G1 (which we have designated G1pm). Upon exposure to growth factor depletion or a lowered de novo protein synthesis, the normal cells leave the cell cycle from G1pm and enter G0. The G1 pm phase is characterized by a remarkably constant length (the duration of which is 3 h in Swiss 3T3 cells), whereas the intercellular variability of intermitotic time is mainly ascribable to late G1 or pre S phase (G1ps) (Zetterberg & Larsson (1985) Proc. Natl. Acad. Sci. USA 82, 5365). As shown in the present study two tumour-transformed derivatives of mouse fibroblasts, i.e. BPA31 and SVA31, did not respond at all, or only responded partially, respectively, to serum depletion and inhibition of protein synthesis. If the tumour cells instead were subjected to 25-hydroxycholesterol (an inhibitor of 3-hydroxy-3 methyglutaryl coenzyme A reductase activity), their growth was blocked as measured by growth curves and [3H]-thymidine uptake. Time-lapse analysis revealed that the cells were blocked specifically in early G1 (3-4 h after mitosis), and DNA cytometry confirmed that the arrested cells contained a G1 amount of DNA. Closer kinetic analysis revealed that the duration of the postmitotic phase containing cells responsive to 25-hydroxycholesterol was constant. These data suggest that transformed 3T3 cells also contain a 'G1pm program', which has to be completed before commitment to mitosis. By repeating the experiments on a large number of tumour-transformed cells, including human carcinoma cells and glioma cells, it was demonstrated that all of them possessed a G1pm-like stage. Our conclusion is that G1pm is a general phenomenon in mammalian cells, independent of whether the cells are normal or neoplastic.
Department of Tumor Pathology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.
O
O
Larsson
A
A
Zetterberg
D016475:3T3 Cells / Q000473:pathology; D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002461:Cell Line, Transformed; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D003513:Cycloheximide / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D005347:Fibroblasts / Q000737:chemistry / Q000473:pathology*; D016193:G1 Phase / Q000502:physiology; D005910:Glioma / Q000473:pathology; D006801:Humans; D006888:Hydroxycholesterols / Q000494:pharmacology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D051379:Mice; D008807:Mice, Inbred BALB C; D008938:Mitosis / Q000502:physiology*; D009369:Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000503:physiopathology; D013997:Time Factors; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; D006888:Hydroxycholesterols; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C007997:25-hydroxycholesterol; D003513:Cycloheximide